Pages that link to "Q38316819"
Jump to navigation
Jump to search
The following pages link to Mechanism and function of a newly identified CpG DNA motif in human primary B cells (Q38316819):
Displaying 50 items.
- Cell cycle progression of chronic lymphocytic leukemia cells is controlled by cyclin D2, cyclin D3, cyclin-dependent kinase (cdk) 4 and the cdk inhibitor p27 (Q24292474) (← links)
- Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7 (Q24295641) (← links)
- DOCK8 functions as an adaptor that links TLR-MyD88 signaling to B cell activation (Q24321675) (← links)
- Structure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery system (Q27004381) (← links)
- Combination of liposomal CpG oligodeoxynucleotide 2006 and miltefosine induces strong cell-mediated immunity during experimental visceral leishmaniasis (Q27341915) (← links)
- Adjuvants for peptide-based cancer vaccines (Q28072236) (← links)
- CpG oligodeoxynucleotides as mucosal adjuvants (Q28086998) (← links)
- Mitigating the looming vaccine crisis: production and delivery of plasmid-based vaccines (Q28294355) (← links)
- Guanine-modified inhibitory oligonucleotides efficiently impair TLR7- and TLR9-mediated immune responses of human immune cells (Q28543539) (← links)
- Nonagonistic Dectin-1 ligand transforms CpG into a multitask nanoparticulate TLR9 agonist (Q30573156) (← links)
- The plasmid pcDNA3 differentially induces production of interferon-alpha and interleukin-6 in cultures of porcine leukocytes (Q30653006) (← links)
- Exploring the native human antibody repertoire to create antiviral therapeutics (Q30835752) (← links)
- Necessity of oligonucleotide aggregation for toll-like receptor 9 activation (Q31074458) (← links)
- A hexanucleotide selected for increased cellular uptake in cis contains a highly active CpG-motif in human B cells and primary peripheral blood mononuclear cells (Q33265100) (← links)
- Conditional immortalization of human B cells by CD40 ligation (Q33316020) (← links)
- Comparison of human B cell activation by TLR7 and TLR9 agonists (Q33354786) (← links)
- Intranasal immunization of mice with a bovine respiratory syncytial virus vaccine induces superior immunity and protection compared to those by subcutaneous delivery or combinations of intranasal and subcutaneous prime-boost strategies (Q33613442) (← links)
- Epigenetic analysis of HIV-1 proviral genomes from infected individuals: predominance of unmethylated CpG's. (Q33768729) (← links)
- Formulation with CpG oligodeoxynucleotides prevents induction of pulmonary immunopathology following priming with formalin-inactivated or commercial killed bovine respiratory syncytial virus vaccine (Q33781642) (← links)
- Microbial Antigens Stimulate Metalloprotease-7 Secretion in Human B-Lymphocytes Using mTOR-Dependent and Independent Pathways (Q33818813) (← links)
- Contribution of IRF5 in B cells to the development of murine SLE-like disease through its transcriptional control of the IgG2a locus (Q33933077) (← links)
- Prevention and treatment of cutaneous leishmaniasis in primates by using synthetic type D/A oligodeoxynucleotides expressing CpG motifs (Q33946716) (← links)
- Immune effects and therapeutic applications of CpG motifs in bacterial DNA. (Q34014839) (← links)
- Causing a commotion in the blood: immunotherapy progresses from bacteria to bacterial DNA. (Q34079342) (← links)
- Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells (Q34083770) (← links)
- Plasmacytoid dendritic cells: the key to CpG. (Q34164404) (← links)
- Positive T cell co-stimulation by TLR7/8 ligands is dependent on the cellular environment (Q34242591) (← links)
- Induction of CD8 T-cell-specific systemic and mucosal immunity against herpes simplex virus with CpG-peptide complexes (Q34340988) (← links)
- Antisense therapy in oncology: new hope for an old idea? (Q34341868) (← links)
- Improved Performance of Anti-miRNA Oligonucleotides Using a Novel Non-Nucleotide Modifier (Q34367048) (← links)
- TLR-based immune adjuvants. (Q34400322) (← links)
- Effect of immunostimulatory CpG-oligonucleotides in chronic lymphocytic leukemia B cells (Q34431577) (← links)
- Spontaneous production of immunoglobulin M in human epithelial cancer cells (Q34516619) (← links)
- DNA mucosal HIV vaccine in humans (Q34556298) (← links)
- Early development of the Toll-like receptor 9 agonist, PF-3512676, for the treatment of patients with advanced cancers (Q34619324) (← links)
- Optimal oligonucleotide sequences for TLR9 inhibitory activity in human cells: lack of correlation with TLR9 binding (Q34647633) (← links)
- CpG DNA modulates interleukin 1beta-induced interleukin-8 expression in human bronchial epithelial (16HBE14o-) cells (Q34722393) (← links)
- CpG DNA as a vaccine adjuvant. (Q35025722) (← links)
- Aggregation and secondary loop structure of oligonucleotides do not determine their ability to inhibit TLR9 (Q35058952) (← links)
- CpG Oligodeoxynucleotide 2006 and Miltefosine, a Potential Combination for Treatment of Experimental Visceral Leishmaniasis (Q35065830) (← links)
- Immunostimulatory DNA for asthma: better than eating dirt (Q35133167) (← links)
- Immunomodulatory spherical nucleic acids (Q35279697) (← links)
- Down-regulation of ATP-binding cassette transporter G1 expression by unmethylated CpG oligodeoxynucleotides in RAW 264.7 macrophages (Q35463935) (← links)
- Cytotoxic-T-lymphocyte human papillomavirus type 16 E5 peptide with CpG-oligodeoxynucleotide can eliminate tumor growth in C57BL/6 mice (Q35543857) (← links)
- Differential signaling by CpG DNA in DCs and B cells: not just TLR9 (Q35557262) (← links)
- Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates (Q35571281) (← links)
- Traditional biochemical assays for studying toll-like receptor 9. (Q35671392) (← links)
- Immunotherapeutic uses of CpG oligodeoxynucleotides (Q35730784) (← links)
- Use of CpG oligodeoxynucleotides as immune adjuvants (Q35826404) (← links)
- Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant (Q35842287) (← links)